Sector consensus Arrowhead Pharmaceuticals, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 20:18:52 22/01/2026 GMT			5-day change	1st Jan Change
69.60 ^USD	+2.97%		+4.94%	+4.72%

01:14pm	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
ARROWHEAD PHARMACEUTICALS, INC.	US$80.18	+18.61%	11
ARGENX SE	€824.2	+18.42%	15
WUXI APPTEC CO., LTD.	CN¥129.23	+31.13%	18
INSMED INCORPORATED	US$213.94	+36.86%	18
BIONTECH SE	US$119.16	+17.14%	19
WUXI BIOLOGICS (CAYMAN) INC.	HK$36.58	+6.72%	25
GENMAB A/S	DKK 2,188.94	+4.83%	13
AKESO, INC.	HK$154.02	+51.36%	22
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	HK$532.76	+24.07%	17
SUMMIT THERAPEUTICS INC.	US$24.22	+92.44%	13
EXELIXIS, INC.	US$45.61	+1.79%	18
MADRIGAL PHARMACEUTICALS, INC.	US$635.21	+27.82%	14
NUVALENT, INC.	US$141.71	+29.96%	17
CYTOKINETICS, INCORPORATED	US$89.44	+41.89%	18
REMEGEN CO., LTD.	HK$77.61	-7.36%	15
ABL BIO INC.	₩124,500	-29.7%	6
Average	8,112.05	+22.87%	16
Weighted average by Cap.	3,195.99	+24.28%	17